Jacqueline Barry serves as the Chief Clinical Officer and Executive Director of the Cell and Gene Therapy Catapult, overseeing Clinical Translation and Delivery activities. With extensive experience in advanced therapy medicinal products, she leads a multi-disciplinary team of Nonclinical, Regulatory, Clinical Operations, and Programme Management specialists. Additionally, Jacqueline coordinates the UK Advanced Therapy Treatment Centre Network and holds a Director position at the Global Alliance for iPSC Therapies.
Jacqueline’s passion lies in making advanced therapies accessible to patients, and she collaborates closely with the MHRA and NHS to develop ecosystems that facilitate the adoption of these therapies.
Before joining the Cell and Gene Therapy Catapult, Jacqueline worked at the Scottish National Blood Transfusion Service, where she designed the regulatory strategy for Cellular Therapies for the Blood Transfusion Service, among other responsibilities. She also acted as a Qualified Person for their release. Jacqueline holds a PhD from the University of Aberdeen and conducted post-doctoral research in neurophysiology at the University of Edinburgh.